

The use of Endoret PRGF in ocular surface diseases

Endoret® PRGF® (plasma rich in growth factors) is a Health Canada licensed technology for obtaining autologous proteins from the patient's own blood.

Advantages of PRGF®

- Autologous and rich in growth factors
- Optimal concentration of growth factors
- Free from leukocytes and inflammatory proteins
- Controlled activation
- Scientific evidence

Case 3: Chronic ADDE with MGD, Candidate for Cataract Surgery

Current Treatment:

Without improvement to baseline symptoms

- 74-year-old female
- Severe dryness persisting for over 10 years
- Mixed aqueous tear deficiency and MGD
- Wears contact lenses for high hyperopia – wants to have CE/IOL
- Non-preserved artificial tears
- Dexamethasone
- Punctal occlusion
- Restasis
- Albumin drops (stopped when Endoret was added)

Clinical Assessment

	Baseline Endoret added Oct. 7, 2021	FU Nov. 15, 2021	FU Dec, 2021
Symptoms	Fluctuating vision, irritation	Same	"My eyes have never felt this good."
TBUT	5 seconds	Improved	Improved
TMH	0.2 mm	Improved	Improved
Corneal Staining	Diffuse, grade 2	No stain	No stain

Case series report: **The use of Endoret PRGF in Ocular Surface Diseases**
By Dr. Rookaya Mather, MD, FRCSC, FACS

Progress and Outcomes


- The patient reported no adverse effects from Endoret treatment, expressed satisfaction with the results, and chose to continue therapy.
- Subsequently had uneventful cataract surgery with a positive outcome.
- This case highlights the role of Endoret PRGF in addressing DED prior to cataract surgery.
- Understanding the poor condition of the cornea and its impact on cataract surgery outcomes, patient agreed to delay the surgery.
- She opted for Endoret treatment.

This case underscores the need for a healthy corneal surface before cataract surgery, highlighting the potential of Endoret PRGF in managing long-term dry eye in such patients.

To listen to

Unlocking Hope For Refractory Sjögren's Syndrome Patients

by Dr. Rookaya Mather, MD, FRCSC, FACS



Dr. Mather's **White Paper**



Dr. Mather's **Webinar**

Case series report: **The use of Endoret PRGF in Ocular Surface Diseases**
By Dr. Rookaya Mather, MD, FRCSC, FACS